Recombinant TIMP-1-GPI inhibits growth of fibrosarcoma and enhances tumor sensitivity to doxorubicin

Overall CM, Kleifeld O (2006) Tumour microenvironment—opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6:227–239 Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387–2392 Kruger A, Kates RE, Edwards DR (2010) Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim Biophys Acta 1803:95–102 Ward RV, Hembry RM, Reynolds JJ, Murphy G (1991) The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex. Demonstration of the biochemical similarities of tissue inhibitor of metalloproteinases-2 and tissue inhibitor of metalloproteinases-1. Biochem J 278(Pt 1):179–187 Howard EW, Bullen EC, Banda MJ (1991) Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2. J Biol Chem 266:13070–13075 Quantin B, Murphy G, Breathnach R (1989) Pump-1 cDNA codes for a protein with characteristics similar to those of classical collagenase family members. Biochemistry 28:5327–5334 Knauper V, Osthues A, DeClerck YA, Langley KE, Blaser J et al (1993) Fragmentation of human polymorphonuclear-leucocyte collagenase. Biochem J 291(Pt 3):847–854 Murphy G, Segain JP, O’Shea M, Cockett M, Ioannou C et al (1993) The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase. J Biol Chem 268:15435–15441 Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG et al (1998) Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161:6845–6852 Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G (1996) Biochemical characterization of human collagenase-3. J Biol Chem 271:1544–1550 English WR, Puente XS, Freije JM, Knauper V, Amour A et al (2000) Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2. J Biol Chem 275:14046–14055 Stracke JO, Hutton M, Stewart M, Pendas AM, Smith B et al (2000) Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J Biol Chem 275:14809–14816 English WR, Velasco G, Stracke JO, Knauper V, Murphy G (2001) Catalytic activities of membrane-type 6 matrix metalloproteinase (MMP25). FEBS Lett 491:137–142 Uria JA, Lopez-Otin C (2000) Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res 60:4745–4751 Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM et al (1989) Antisense RNA induced reduction in murine TIMP levels confers oncogenicity on Swiss 3t3-Cells. Science 243:947–950 Declerck YA, Perez N, Shimada H, Boone TC, Langley KE et al (1992) Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52:701–708 Alonso DF, Skilton G, De Lorenzo MS, Scursoni AM, Yoshiji H et al (1998) Histopathological findings in a highly invasive mouse mammary carcinoma transfected with human tissue inhibitor of metalloproteinases-1. Oncol Rep 5:1083–1087 Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A (1994) Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 107(Pt 9):2373–2379 Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K (1992) Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298:29–32 Yoshiji H, Harris SR, Raso E, Gomez DE, Lindsay CK et al (1998) Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 75:81–87 Goss KJ, Brown PD, Matrisian LM (1998) Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int J Cancer 78:629–635 Kruger A, Fata JE, Khokha R (1997) Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood 90:1993–2000 Medof ME, Nagarajan S, Tykocinski ML (1996) Cell-surface engineering with GPI-anchored proteins. FASEB J 10:574–586 Djafarzadeh R, Milani V, Rieth N, von Luettichau I, Skrablin PS et al (2009) TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis. Cancer Immunol Immunother 58:361–371 Djafarzadeh R, Mojaat A, Vicente AB, von Luttichau I, Nelson PJ (2004) Exogenously added GPI-anchored tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) displays enhanced and novel biological activities. Biol Chem 385:655–663 Djafarzadeh R, Noessner E, Engelmann H, Schendel DJ, Notohamiprodjo M et al (2006) GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing. Oncogene 25:1496–1508 Djafarzadeh R, Sauter M, Notohamiprodjo S, Noessner E, Goyal P et al (2012) Recombinant GPI-anchored TIMP-1 stimulates growth and migration of peritoneal mesothelial cells. PLoS One 7:e33963 Schmuck R, Warneke V, Behrens HM, Simon E, Weichert W et al (2011) Genotypic and phenotypic characterization of side population of gastric cancer cell lines. Am J Pathol 178:1792–1804 Marquardt JU, Raggi C, Andersen JB, Seo D, Avital I et al (2011) Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology 54:1031–1042 Wang CYY, Wei QX, Han I, Sato S, Ghanbari-Azarnier R et al (2012) Hedgehog and notch signaling regulate self-renewal of undifferentiated pleomorphic sarcomas. Cancer Res 72:1013–1022 Rasheed S, Nelson-Rees WA, Toth EM, Arnstein P, Gardner MB (1974) Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer 33:1027–1033 Kirby AC, Hill V, Olsen I, Porter SR (1995) LFA-3 delta D2: a novel in vivo isoform of lymphocyte function-associated antigen 3. Biochem Biophys Res Commun 214:200–205 Mack M, Riethmuller G, Kufer P (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A 92:7021–7025 Raggi MC, Djafarzadeh R, Muenchmeier N, Hofstetter M, Jahn B et al (2009) Peritumoral administration of GPI-anchored TIMP-1 inhibits colon carcinoma growth in Rag-2 gamma chain-deficient mice. Biol Chem 390:893–897 Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 274:21491–21494 Hu J, Van den Steen PE, Sang QX, Opdenakker G (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6:480–498 Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174 Kopitz C, Gerg M, Bandapalli OR, Ister D, Pennington CJ et al (2007) Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res 67:8615–8623 Brew K, Dinakarpandian D, Nagase H (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477:267–283 Klier CM, Nelson EL, Cohen CD, Horuk R, Schlondorff D et al (2001) Chemokine-induced secretion of gelatinase B in primary human monocytes. Biol Chem 382:1405–1410 Bode W, Maskos K (2003) Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. Biol Chem 384:863–872 Sohail A, Sun Q, Zhao H, Bernardo MM, Cho JA et al (2008) MT4-(MMP17) and MT6-MMP (MMP25), a unique set of membrane-anchored matrix metalloproteinases: properties and expression in cancer. Cancer Metastasis Rev 27:289–302 Liotta LA, Kohn EC (2001) The microenvironment of the tumour–host interface. Nature 411:375–379 Bandapalli OR, Paul E, Schirmacher P, Brand K (2012) Opposite effects of tissue inhibitor of metalloproteinases-1 (TIMP-1) over-expression and knockdown on colorectal liver metastases. BMC Res Notes 5:14 Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360 Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P et al (1998) In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102:2002–2010 Davidsen ML, Wurtz SO, Romer MU, Sorensen NM, Johansen SK et al (2006) TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 95:1114–1120 Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H et al (2006) Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44:240–251 Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K et al (2006) Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24:506–513